Thursday, November 6, 2014

Scalability and cost,Pfizer's reason for different approach

“We would like to take it to the next level, where CAR therapies become a more standardized, highly controlled treatment,” said Mikael Dolsten, Pfizer’s head of global research and development.
Working with French biotech Cellectis SA, ALCLS.FR -2.65% Pfizer wants to develop a generic CAR therapy for use in any patient, potentially lowering its cost. But its research is still preclinical, and may not work in humans.
Stephen McGarry, global head of health-care research at Société Générale, agrees the treatments being developed by Novartis and Juno could justify “astronomical” prices, although he thinks health-care payers and patients might fight back.
“When you look at the initial data with the Novartis therapy, you’re getting cures in some kids—what do you charge for that?” he asks

No comments:

Post a Comment